GlassScriptPhysician profile
Emily Shtull
NPI 1023781960
$2,669.90
in general payments reported to CMS, 2019-2025
18 companies · $642 in 2025
The $642 reported for 2025 was more than what 83% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $231 · 2022: $411 · 2023: $528 · 2024: $857 · 2025: $642.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,028.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,027.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $497.82 | 2022-2025 | Rocklatan, Precision7, Rhopressa |
| Biotissue Holdings INC. | $323.34 | 2021-2024 | |
| Dompe US, INC. | $290.33 | 2024-2025 | Oxervate |
| Oyster Point Pharma, INC. | $288.17 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Abbvie INC. | $218.60 | 2023-2025 | Lumigan, Vuity, Alphagan P |
| Bausch & Lomb Americas INC. | $201.15 | 2023-2025 | Miebo, Xiidra, Alden Scleral Zenlens |
| Rxsight INC | $146.70 | 2025 | Rxsight Contact Lens, Light Adjustable Lens (Lal), Rxsight Injector Cartridge |
| Eyepoint US, INC. | $143.25 | 2022 | |
| Allergan, INC. | $122.43 | 2021 | |
| Coopervision INC. | $100.67 | 2024 | Paragon Crt |
| Johnson & Johnson Vision Care, INC. | $79.54 | 2022 | |
| Harrow Eye, LLC | $57.40 | 2024-2025 | Vevye |
| Astellas Pharma US INC | $57.27 | 2023-2024 | Izervay |
| Sun Pharmaceutical Industries INC. | $51.71 | 2021-2024 | |
| Apellis Pharmaceuticals, INC. | $34.77 | 2023 | Syfovre |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $21.22 | 2023 | Tepezza |
| Eyevance Pharmaceuticals LLC | $19.88 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $15.65 | 2024 | Xdemvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Shtull listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.